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Abstract: Olopatadine hydrochloride exerts a wide range of pharmacological actions such as 
histamine H1 receptor antagonist action, chemical mediator suppressive action, and eosinophil 
inﬁ  ltration suppressive action. Olopatadine hydrochloride 0.1% ophthalmic solution (Patanol®) 
was introduced to the market in Japan in October 2006. In a conjunctival allergen challenge 
(CAC) test, olopatadine hydrochloride 0.1% ophthalmic solution signiﬁ  cantly suppressed 
ocular itching and hyperemia compared with levocabastine hydrochloride 0.05% ophthalmic 
solution, and the number of patients who complained of ocular discomfort was lower in the 
olopatadine group than in the levocabastine group. Conjunctival cell membrane disruption was 
observed in vitro in the ketotifen fumarate group, epinastine hydrochloride group, and azelastine 
hydrochloride group, but not in the olopatadine hydrochloride 0.1% ophthalmic solution group, 
which may potentially explain the lower discomfort felt by patients on instillation. Many other 
studies in humans have revealed the superiority of olopatadine 0.1% hydrochloride eye drops 
to several other anti-allergic eye drops. Overseas, olopatadine hydrochloride 0.2% ophthalmic 
solution for a once-daily regimen has been marketed under the brand name of Pataday®. It is 
expected that olopatadine hydrochloride ophthalmic solutions may be used in patients with a 
more severe spectrum of allergic conjunctival diseases, such as vernal keratoconjunctivitis or 
atopic keratoconjunctivitis, in the near future.
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Introduction
The prevalence of allergic conjunctival diseases (ACD) in Japan is estimated to be 
as high as 15%–20% of the population and is on the rise. Cases of seasonal allergic 
conjunctivitis (SAC) due to cedar pollen account for a major part of allergic conjunc-
tivitis (AC) in Japan. Cedar pollinosis presents not only with nasal symptoms such as 
sneezing and rhinorrhea, but also with severe ocular itching. Ocular itching and nasal 
symptoms adversely affect the quality of life (QoL) of patients. In addition, the recent 
increase in severity of ACD is raising concerns.
ACD are ocular disorders caused by allergic inﬂ  ammation of the ocular surface, 
and include AC, atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC), 
and giant papillary conjunctivitis (GPC). The clinical features of ACD are character-
ized by their wide variety, and the medical treatment of ACD should be based on the 
clinical characteristics. AC is deﬁ  ned as ACD in which the conjunctiva shows no pro-
liferative change, and is divided into two subcategories, SAC and perennial allergic 
conjunctivitis (PAC), according to the presence of seasonal exacerbation. PAC is a less 
severe ACD, though still uncomfortable for the patient. Signs and symptoms of PAC 
include itching, hyperemia, and tearing. Mucous discharge is clear and transient. AKC 
is a bilateral, chronic hypersensitivity disease of the ocular surface seen in association 
with systemic atopic dermatitis, characterized by lesions of the conjunctiva and cornea 
that vary in severity. Ocular symptoms include intense itching, photophobia, burning, Clinical Ophthalmology 2008:2(3) 526
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and the sensation of a foreign body. The clinical signs show 
a wide spectrum, and in the most severe cases, conjunctival 
scarring with subepithelial ﬁ  brosis, fornix foreshortening, 
symblepharon and corneal ulceration, and neovasculariza-
tion may occur. Therefore, it is a sight-threatening condi-
tion, emerging in the second through the ﬁ  fth decade of life 
(Belfort et al 2000). The disease is associated with eczema 
of the lids or other parts of the body. VKC is a recurrent sea-
sonal disease of childhood, characterized by severe bilateral 
inﬂ  ammation of the conjunctiva and by giant papillae of the 
superior tarsal conjunctiva, gelatinous hypertrophy of the 
limbus, and keratopathy. It is associated with intense itching, 
photophobia, and mucous discharge, and is most commonly 
seen in male patients. However, unlike the severe group of 
AKC, it tends to resolve spontaneously after several years. 
The incidence of VKC varies markedly with geographic 
location, with individuals in Italy, Japan, and other areas of 
warm climate being more likely to have the disease (Calonge 
1999; Ono and Abelson 2005).
For the treatment of ACD, several local ocular drugs, such 
as antihistamines, anti-allergic agents, and corticosteroids, 
have been developed as commercially available eye drops 
recently. Anti-allergic eye drops products which are the 
basic therapy for ACD are classiﬁ  ed into 2 types based on 
their pharmacological characteristics: drugs that suppress the 
release of a mediator (eg, disodium cromoglycate) and his-
tamine H1 antagonists. Especially, histamine H1 antagonists 
are recommended as the ﬁ  rst choice of treatment for cases 
with severe nasal symptoms and itching because prompt 
symptom relief is expected.
As of 2005, 6 mediator release suppression agents 
(disodium cromoglycate, amlexanox, pemirolast potassium, 
tranilast, ibudilast, and acitazanolast hydrate) and 2 histamine 
H1 antagonists (ketotifen fumarate and levocabastine hydro-
chloride) are used in commercially available anti-allergic eye 
drops products in Japan. Although prescriptions of eye drops 
containing histamine H1 antagonists have recently increased 
because of their superior rapid effect, only 2 eye drops, 
ketotifen fumarate 0.05% and levocabastine hydrochloride 
0.025%, were available at that time in Japan; in contrast, more 
anti-histaminergic eye drops were available worldwide.
Olopatadine hydrochloride, developed by Kyowa Hakko 
Kogyo Co., Ltd. (Tokyo, Japan), exerts a wide range of phar-
macological actions such as histamine H1 receptor antagonist 
action, chemical mediator suppressive action, tachykinin 
release inhibitory action, and eosinophil inﬁ  ltration suppres-
sive action. In Japan, a formulation for oral use that is highly 
evaluated by physicians and is indicated for allergic rhinitis, 
urticaria, and itching associated with dermatosis (eczema and 
dermatitis, prurigo, pruritus cutaneous, psoriasis vulgaris, and 
erythema exsudativum multiforme) has been marketed since 
March 2001 (Ohmori et al 2002). Alcon Inc. (Hünenberg, 
Switzerland) developed an olopatadine hydrochloride oph-
thalmic solution under license from Kyowa Hakko Kogyo 
Co., Ltd. Since 1996, the product has been approved in about 
90 countries, including the US, and at present it is widely 
used in clinical practice to treat AC.
In Japan, olopatadine hydrochloride 0.1% ophthalmic 
solution was introduced to the market in October 2006 as a 
third anti-histaminergic eye drop, in addition ketotifen fuma-
rate and levocabastine hydrochloride. This article reviews 
the pharmacological actions and clinical effects of the new 
olopatadine hydrochloride ophthalmic solution.
Pharmacological properties
ACD are mainly caused by type I allergic reactions. When 
IgE antibodies speciﬁ  c to pollen or house dust are exces-
sively produced, an antigen-antibody reaction is induced, 
leading to degranulation of mast cells. Then, mast cells 
release chemical mediators such as histamine, triggering the 
development of symptoms. Although such allergic reactions 
involve various chemical mediators, conjunctival symptoms 
such as ocular itching and conjunctival hyperemia are devel-
oped by histaminergic actions mainly through H1 receptors 
(Knight 1994).
Histamine H1 receptor selectivity of olopatadine hydro-
chloride was examined using brain homogenates from guinea 
pigs and rats. Afﬁ  nity for H1, H2, and H3 receptors was exam-
ined using pyrilamine, tiotidine, and methylhistamine as the 
ligand, respectively. Ki (afﬁ  nity) values of the olopatadine 
hydrochloride binding to H1, H2, and H3 receptors were 
4.11 × 10−8 M, 4.34 × 10−5 M, and 1.72 × 10−4 M, respectively, 
indicating that selectivity for H1 receptors is about 1000 times 
that for H2 receptors and 4000 times that for H3 receptors. 
The selectivity of olopatadine hydrochloride is higher than 
that of ketotifen fumarate or levocabastine hydrochloride 
(Sharif et al 1996). Compared with disodium cromoglycate, 
nedocromil, and pemirolast potassium, only olopatadine 
hydrochloride suppressed antigen-induced histamine from 
human conjunctival mast cells in a dose-dependent manner 
(IC50: 6.53 × 10−4 M) (Yanni et al 1997).
Olopatadine hydrochloride suppressed TNF-α release in 
vitro from human conjunctival mast cells in a concentration-
dependent manner (IC50: 1.3 ×10−5 M) (Cook et al 2000), as 
well as that of interleukin 6 (IL-6) and IL-8 from conjunc-
tival epithelial cells (IC50: 5.5 × 10−9 M and 1.7 × 10−9 M, Clinical Ophthalmology 2008:2(3) 527
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respectively) (Yanni et al 1999). The effects of olopatadine 
hydrochloride on type I allergy have also been examined in 
vivo. Guinea pigs were passively sensitized through adminis-
tration of anti-ovalbumin (OVA) serum into the conjunctival 
sac, and then olopatadine hydrochloride was instilled into their 
eyes. Thirty minutes after the administration, its effect on 
passive anaphylactic reaction was evaluated by intravenously 
administering solution containing OVA and Evans blue. As 
a result, 0.001%–0.1% olopatadine hydrochloride showed a 
dose-dependent suppressive effect, with the 50% effective 
dose (ED50) being 0.0067%. Moreover, the passive anaphylac-
tic reaction induced in guinea pigs by instillation of the antigen 
after sensitization with anti-OVA serum was signiﬁ  cantly 
suppressed when 0.001%–1.0% olopatadine hydrochloride 
was instilled into the eyes 30 minutes before the induction 
(ED50: 0.017%). The effect of olopatadine hydrochloride on 
enhanced vascular permeability induced by histamine in the 
conjunctiva of guinea pigs ranged between concentrations of 
0.00001% to 1.0%. Olopatadine hydrochloride suppressed the 
reaction in a concentration-dependent manner. Signiﬁ  cant 
suppression was observed at 0.1% for 24 hours compared 
with that in a control group in which physiological saline was 
instilled into the eyes (Yanni et al 1996).
Olopatadine hydrochloride is considered as a promising 
dual-action drug with selective and continuous histamine H1 
receptor antagonistic action and mast cell stabilization action.
Clinical trials in Japan
Olopatadine hydrochloride 0.1% ophthalmic solution is 
marketed worldwide as Patanol® Ophthalmic Solution 
0.1%. In Japan its approved dosage and administration for 
allergic conjunctivitis is 1–2 drops qid. At the beginning of 
its development in Japan, approval for instillation bid at the 
same dosage was considered for convenience of clinical use. 
However, in Japan, most anti-allergic eye drops products are 
used qid, because patients with severe ocular itching caused 
by cedar pollinosis tend to prefer to instill more than twice 
per day. Another reason was that the higher frequency of 
instillations might have a better antigen ﬂ  ushing effect. An 
open study was conducted to examine the potential increase 
of adverse reactions with a higher frequency of instilla-
tion. The study compared a bid group with a qid group, 44 
patients in each, during the cedar-pollen-shedding period 
using an environmental study protocol. Effects on itching 
and hyperemia were comparable in both groups; however, 
the qid group showed slightly lower incidence of adverse 
drug reactions than the bid group (bid group, 15.9%; qid 
group, 9.1%) (Saiga et al 2006). Based on these results and 
the aforementioned reasons, the qid regimen was adopted. A 
double-blind phase III study that involved 247 patients with 
Japanese cedar pollen AC was conducted using the environ-
mental study protocol mentioned above. The study compared 
olopatadine hydrochloride 0.1% ophthalmic solution with 
ketotifen fumarate 0.05% ophthalmic solution (a control 
drug), both at a dose of 2 drops qid for 28 days. Olopatadine 
hydrochloride 0.1% eye drops proved to be as effective (ocu-
lar itching and conjunctival hyperemia) as ketotifen fumarate 
0.05% eye drops. The incidence of adverse reactions was 
4.8% (6/124 patients) in the olopatadine group and 20.3% 
(25/123 patients) in the ketotifen group (p = 0.0002, Fisher’s 
exact test) (Saiga 2006). Thereafter, a long-term study was 
carried out in 20 patients with AC in which the study drug 
was administered at the same dose but for 70 days (Saiga et al 
2005). The patients were evaluated every 2 weeks using an 
ocular itching and conjunctival hyperemia scale. The ocular 
itching score decreased with time during treatment: 3.55 ± 
1.2 (mean ± SD) at baseline, 2.85 ± 1.5 at 2 weeks, 2.13 ± 
1.4 at 4 weeks, 2.08 ± 1.7 at 6 weeks, 1.75 ± 1.7 at 8 weeks, 
and 1.63 ± 1.7 at 10 weeks. The conjunctival hyperemia score 
showed a similar tendency; signs and symptoms markedly 
improved after the prolonged treatment period. No adverse 
reaction was observed, demonstrating the efﬁ  cacy and toler-
ability of olopatadine hydrochloride 0.1% eye drops in the 
long-term treatment.
Clinical evaluation of olopatadine 
hydrochloride in CAC study
Conjunctival allergen challenge (CAC) was developed by 
Abelson et al (1990) to evaluate the efﬁ  cacy of anti-allergic 
ophthalmic solutions. CAC facilitates the evaluation, because 
in patients conﬁ  rmed to have antigen sensitivity, conjuncti-
val allergic reaction is reproduced by antigen challenge at a 
standardized exact concentration, and then clinical symptoms 
are recorded based on evaluation scales described in the 
protocol. Because it also allows comparison between right 
and left eyes in the same individual, it is less likely to be 
affected by variations in individual differences than conven-
tional environmental studies. Olopatadine hydrochloride was 
also evaluated for usefulness in terms of duration of action, 
resolution of ocular itching, and comfort upon instillation, 
using the CAC study scheme.
Abelson and Greiner conducted a double-blind CAC 
study that involved 68 patients (Abelson and Greiner 2004). 
Olopatadine hydrochloride 0.1% eye drops and levocabastine 
hydrochloride 0.05% eye drops were randomly assigned to 
the right and left eyes in an individual, in a double-blind Clinical Ophthalmology 2008:2(3) 528
Uchio
manner. After treatment, ocular findings induced by a 
positive antigen were compared within 1 hour of dosing. 
Olopatadine hydrochloride 0.1% ophthalmic solution 
signiﬁ  cantly suppressed ocular itching (3 and 10 minutes 
after antigen induction, p  0.001) and conjunctival 
hyperemia (3, 10, and 20 minutes after antigen induction, 
p  0.0001) compared with levocabastine hydrochloride 
0.05% ophthalmic solution. Fewer patients complained 
of ocular discomfort in the olopatadine group than in the 
levocabastine group. Berdy et al (2000) compared ketotifen 
fumarate 0.025% ophthalmic solution with olopatadine 
hydrochloride 0.1% ophthalmic solution in 32 patients. One 
drop of the respective eye drops was instilled and the eye 
was challenged with the antigen 12 hours later. Olopatadine 
hydrochloride signiﬁ  cantly reduced the itching score (3, 
5, and 10 minutes after antigen induction, p  0.05) and 
comfort score (p  0.05) compared with ketotifen fumarate. 
Thus, these CAC study results showed that the effects of 
olopatadine hydrochloride 0.1% ophthalmic solution are 
observed within a few minutes after antigen challenge and 
they last for considerably long period.
Ohno et al (2007) conducted a CAC study that involved 
20 Japanese (including patients of Japanese descent) 
patients with ACD (including Japanese cedar pollinosis) to 
compare olopatadine hydrochloride 0.1% eye drops with 
levocabastine hydrochloride 0.025% eye drops for efﬁ  cacy 
and comfort (Ohno et al 2007). Each eye was challenged 
with the antigen 3.5 hours after any of the two drugs had 
been instilled, and ocular itching was evaluated using 
a 5-grade scale of 0 (absent) to 4 (severe). Olopatadine 
hydrochloride markedly suppressed ocular itching compared 
with levocabastine hydrochloride; the mean score was 42% 
lower in olopatadine hydrochloride-treated eyes than in 
levocabastine hydrochloride-treated eyes. The number of 
responders (subjects with an ocular itching score of 0 after the 
treatment) was signiﬁ  cantly higher in the olopatadine group 
than in the levocabastine group (p  0.05) (Figure 1). In 
contrast, ocular pain (25%) and burning sensation (20%) were 
observed in the levocabastine group, but no such symptoms 
were reported within the olopatadine group. Seventy-ﬁ  ve 
percent (15/20) preferred olopatadine hydrochloride 0.1% 
eye drops to levocabastine hydrochloride 0.025% eye drops 
according to their objective symptoms.
As described above, the results of CAC studies performed 
both in Japan and other countries have demonstrated the 
effectiveness and usefulness of olopatadine hydrochloride 
0.1% ophthalmic solution in reducing ocular symptoms in 
patients with ACD.
Comparison of olopatadine 
hydrochloride with other eye drops
Brockman et al (2003) examined cytotoxicity of each antihis-
tamine in a concentration range at which the drug might be 
present after instillation by measuring lactate dehydrogenase 
(LDH), which is released from human conjunctival cells after 
cell membrane disruption. They reported that cell membrane 
disruption was observed in the ketotifen fumarate 0.025% 
group, epinastine hydrochloride 0.05% group, and azelas-
tine hydrochloride 0.05% group, but not in the olopatadine 
hydrochloride 0.1% ophthalmic solution group, which may 
explain why patients felt less discomfort on instillation. In 
Japan, the aforementioned phase III study showed favorable 
tolerability of olopatadine hydrochloride 0.1% eye drops; in 
addition, Sumi et al (2008) compared the effects and satisfac-
tion rating in 17 patients with Japanese cedar pollinosis who 
had used other anti-allergic eye drops in the previous year 
(levocabastine hydrochloride ophthalmic solution had been 
used by 10 patients, ketotifen fumarate ophthalmic solution 
by 3 patients, others by 2 patients, and unknown drugs by 2 
patients). These patients used olopatadine hydrochloride 0.1% 
ophthalmic solution after the onset of symptoms, and graded 
their ocular itching according to the visual analog scale (VAS). 
The score decreased from 6.59 at baseline to 3.91 at 2 weeks, 
with statistical signiﬁ  cance. The mean difference of the ocular 
itching score from baseline score was 7.38 with olopatadine 
hydrochloride 0.1% ophthalmic solution, which was higher 
than the score reduction obtained in the previous year (4.63). 
The level of satisfaction with treatment was investigated in 
patients who had used the most commonly prescribed levoca-
bastine hydrochloride eye drops in the previous year; 78% of 
the patients preferred olopatadine eye drops to levocabastine 
Figure 1 Percentage of responders: CAC (conjunctival allergen challenge) study 
comparing olopatadine hydrochloride 0.1% ophthalmic solution with levocabastine 
hydrochloride 0.025% ophthalmic solution. Percentage of responders (n = 20).   A 
subject with itching score results of 0 after treatment was deﬁ  ned as a responder. 
*p  0.05.
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eye drops because of higher therapeutic effects and more 
comfortable feeling upon instillation.
Overseas, double-blind, controlled studies using an 
environmental study protocol have reported favorable effects 
and local tolerability of olopatadine hydrochloride 0.1% 
ophthalmic solution. Artal et al (2000) instilled 1 drop of 
olopatadine hydrochloride 0.1% ophthalmic solution into 
either right or left eye, and 1 drop of ketotifen fumarate 0.05% 
ophthalmic solution into the contralateral eye in 80 patients 
to investigate comfort upon instillation. They reported that all 
patients preferred olopatadine hydrochloride 0.1% to keto-
tifen fumarate 0.05%. Aguilar (2000) conducted a random-
ized double-blind controlled study to compare the efﬁ  cacy 
of olopatadine hydrochloride 0.1% eye drops and ketotifen 
fumarate 0.05% eye drops, and tolerability in 80 patients with 
allergic conjunctivitis. These drugs were instilled bid for 14 
days. Olopatadine hydrochloride 0.1% ophthalmic solution 
reduced itching as early as 30 minutes after the instillation 
and a higher percentage of patients reported improvement with 
olopatadine hydrochloride 0.1% ophthalmic solution than with 
ketotifen fumarate 0.05% ophthalmic solution. Aguilar (2000) 
also reported that mild reaction of intolerance (stinging) was 
observed in 23% of the ketotifen fumarate 0.05% ophthalmic 
solution group, but not in the olopatadine hydrochloride 0.1% 
ophthalmic solution group. Katelaris et al (2002) conducted a 
6-week, multicenter, randomized controlled study to compare 
the effects of olopatadine hydrochloride 0.1% ophthalmic solu-
tion and disodium cromoglycate 2% ophthalmic solution on 
itching and hyperemia in 185 patients with seasonal allergic 
conjunctivitis. Group I received olopatadine hydrochloride 
0.1% ophthalmic solution bid and placebo bid, while Group II 
received disodium cromoglycate 2% ophthalmic solution qid 
Itching and hyperemia were suppressed in a signiﬁ  cantly higher 
percentage of patients in Group I (p  0.05, vs Group II), and 
both groups showed favorable tolerability. They also reported 
that in children less than 11 years old, olopatadine hydrochlo-
ride 0.1% ophthalmic solution seemed to be more tolerable 
than disodium cromoglycate 2% ophthalmic solution. It has 
been reported that olopatadine 0.1% ophthalmic solution is 
signiﬁ  cantly more effective than epinastine hydrochloride 
0.05% ophthalmic solution in controlling itching, redness, and 
chemosis associated with allergic conjunctivitis in the CAC 
model (Lanier et al 2004). Spangler et al (2001) compared the 
effect of olopatadine hydrochloride 0.1% ophthalmic solution 
and azelastine hydrochloride 0.05% in the CAC model, and 
found that both treatments were signiﬁ  cantly more effective 
than placebo at reducing itching post challenge; however, 
olopatadine was signiﬁ  cantly more effective than azelastine in 
reducing itching at 3.5 minutes through 20 minutes post chal-
lenge (average mean unit difference of –0.31; p  0.05). In a 
placebo-controlled, randomized, parallel group, single-center 
study, both olopatadine 0.1% and ketorolac 0.5% ophthalmic 
solutions were found to be effective in alleviating the clinical 
signs and symptoms of SAC compared with placebo. However, 
olopatadine reduces ocular itching signiﬁ  cantly more than 
ketorolac (Yaylali et al 2003).
In contrast, in a 30-day, randomized, double-masked, 
artiﬁ  cial tear substitute (ATS)-controlled clinical trial, in both 
active-treatment groups (olopatadine hydrochloride 0.1% 
and ketotifen fumarate 0.025% ophthalmic solutions), the 
improvements in clinical scores (tearing and itching) were 
more pronounced compared with those in the ATS group, 
although the day-30 difference in tearing score between the 
olopatadine and ATS groups was not statistically signiﬁ  cant 
(Avunduk et al 2005). Ganz et al (2003) carried out a 3-week 
prospective, randomized, double-masked, parallel-group study 
to compare ketotifen fumarate 0.025% ophthalmic solution 
and olopatadine hydrochloride 0.1% ophthalmic solution in 
66 patients with SAC. The responder rate was higher with 
ketotifen than with olopatadine on day 5 (72% vs 54% for 
patient assessment, 88% vs 55% for investigator assessment) 
and day 21 (91% vs 55%, 94% vs 42%). Global efﬁ  cacy rat-
ings were also higher with ketotifen, and severity scores for 
hyperemia and itching were signiﬁ  cantly lower. Although the 
reason for these conﬂ  icting results is unclear, differences in 
study design or study population might be the explanation.
Clinical effect of olopatadine 
0.2% eye drops
Overseas, olopatadine hydrochloride 0.2% ophthalmic solu-
tion for a once-daily regimen has been marketed under the 
brand name of Pataday®. Its effect lasts 24 hours (Vogelson 
et al 2004). Abelson et al carried out a randomized double-
blind placebo controlled study using a CAC study protocol 
that involved 23 patients (Abelson et al 2008). Olopatadine 
hydrochloride 0.2% ophthalmic solution was instilled once 
daily into one eye and olopatadine hydrochloride 0.1% oph-
thalmic solution was instilled twice a dally into the contra-
lateral eye. They reported that ocular itching was suppressed 
in both treatment groups compared with a placebo group at 
24 hours, and there was no difference in ocular itching sup-
pression or occurrence of adverse drug reactions between the 
two groups. Mah et al conducted a randomized placebo con-
trolled study using a CAC study protocol in which 92 subjects 
were distributed into 4 groups: olopatadine hydrochloride vs 
placebo, epinastine hydrochloride vs placebo, olopatadine Clinical Ophthalmology 2008:2(3) 530
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hydrochloride vs epinastine hydrochloride, and placebo vs 
placebo (Mah et al 2007). Olopatadine hydrochloride 0.2% 
ophthalmic solution signiﬁ  cantly suppressed ocular itching 
by 5–7 minutes after antigen challenge compared with epi-
nastine hydrochloride 0.05% ophthalmic solution (p = 0.024 
and p = 0.003, respectively), and its effects on conjunctival 
hyperemia and comfort upon instillation were more favorable 
as well (p = 0.003). A placebo-controlled study has also dem-
onstrated the safety proﬁ  le of olopatadine hydrochloride 0.2% 
ophthalmic solution in children and adolescents (Lichtenstein 
et al 2007). Although olopatadine hydrochloride 0.2% eye 
drops cannot be used clinically in Japan, physicians will be 
attracted to the drug in the near future especially because of 
its improved compliance.
Possibility of future optional 
use of olopatadine eye drops
In Japan among pollinosis patients, treatment for nasal symp-
toms has been relatively prioritized, while ocular symptoms 
have not been given sufﬁ  cient importance (Kakutani et al 
2005). Berger et al conducted a prospective multicenter cross-
over study that involved 200 patients with allergic rhinitis. 
Of these, 90.5% had some concurrent ocular symptoms, and   
ocular treatment with olopatadine hydrochloride 0.1% eye 
drops combined with nasal treatment improved ocular allergic 
symptoms and their QOL compared with the nasal treatment 
only (Berger et al 2005). From the results in CAC studies, it 
may be possible that olopatadine hydrochloride 0.1% or 0.2% 
ophthalmic solution has an important role if used for these 
multi-organ cases by resolving ocular symptoms promptly and 
potently. Interestingly, it has been reported that olopatadine 
0.2% ophthalmic solution, relative to placebo, signiﬁ  cantly 
reduced the frequency of pollen effects on sneezing and itchy 
nose, and reduced the severity of pollen effects on sneezing, 
itchy nose, and runny nose, indicating its additional effect on 
nasal allergy (Abelson et al 2005).
For patients with a more severe spectrum of ACD, such as 
VKC and AKC, immunosuppressive eye drops (cyclosporine 
or tacrolimus) have been introduced for topical treatment 
in Japan. It has been reported that 2 months’ treatment 
with olopatadine hydrochloride 0.1% relieves the signs and 
symptoms of VKC (Corum et al 2005). Also, it reduces the 
number of goblet cells, which, in turn, decreases the amount 
of mucus discharge in VKC during treatment. Although 
similar reports are limited at present, this research suggests 
that olopatadine 0.1% eye drops may become an important 
option in the treatment of VKC and AKC.
Conclusions
Olopatadine hydrochloride ophthalmic solution has an 
excellent, strong, and safe anti-allergic effect in vitro and 
it provides superior clinical effectiveness in patients with 
AC compared with other histamine antagonistic ophthalmic 
solutions or non-steroidal anti-inﬂ  ammatory eye drops. 
Also, ACD patients feel signiﬁ  cantly less discomfort upon 
instillation. Although further clinical evaluation is neces-
sary, olopatadine hydrochloride eye drops has the potential 
for simultaneous use with nasal drugs for pollinosis, and 
also may be used in patients with more severe conditions, 
such as VKC or AKC, in the near future.
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